Thanks @scifri.bsky.social for having me on to talk about federal research budgets. TLDL: Congress voted to reject the president's big science cuts, but the White House is slow to release those approved funds. 🧪
podcasts.apple.com/us/podcast/s...
Thanks @scifri.bsky.social for having me on to talk about federal research budgets. TLDL: Congress voted to reject the president's big science cuts, but the White House is slow to release those approved funds. 🧪
podcasts.apple.com/us/podcast/s...
Congress rejected massive cuts to US science budgets for 2026, but much of the money still isn’t flowing to researchers.
The culprit? The White House Office of Management and Budget (OMB) is quietly slow-walking the release of funds. 🧵👇
More researchers face consequences for their links to #Epstein. Jack Horner, who was a consultant for the Jurassic park films, is no longer employed at Chapman University. See my story for Nature www.nature.com/articles/d41...
Today’s action “is a rejection of the most basic laws of physics”, says #climate scientist Friederike Otto.
I report on the EPA revoking its own ruling on the danger of greenhouse gases:
www.nature.com/articles/d41... 🧪
I'm on Capitol Hill watching NIH director Jayanta Bhattacharya testify to the Senate HELP committee.
Thankfully I haven't been escorted out of this event (yet). Here's what I'm following. You can also watch live here:
www.help.senate.gov/hearings/mod...
Aluminium is crucial to vaccines — and safe. Why are US advisers debating it? www.nature.com/articles/d41... by @heidiledford.bsky.social via @nature.com
"You cannot just get rid of an adjuvant that works and is safe before you have something else that you know will be a good replacement."
Too kind, Nick! Can't wait to listen to the podcast
Inspired by Fred Rogers, @nature.com asked readers to help us 'find the helpers' amid the crisis in American science. What emerged were inspiring stories of researchers, legal experts, data hounds and government scientists who are fighting the dismantling of the US research enterprise. 🧪🧵1/6
Often the news happens so quickly that there's little time for it, so we took a step back to talk about the stories of the researchers who have been fighting back against the Trump administration's assault on science.
w/ @maxkozlov.bsky.social and @heidiledford.bsky.social
YES!!!! So happy to see @maxkozlov.bsky.social recognized for the total rockstar he is: casw.org/news/max-koz...
So many more schmancy journalism awards in this guy's future.
Scientists are closing in on the ability to apply genome editing to a formidable new target: the human brain
go.nature.com/45uKWT1
The claim that aluminium in vaccines causes autism has been debunked “again and again”
go.nature.com/4mY7OQQ
In which @stephaniemlee.bsky.social reports for @theopennotebook.bsky.social on using public documents for investigative science journalism. With @laurenweberhp.bsky.social @naveenasadasivam.bsky.social @primateyell.bsky.social @dangaristo.bsky.social & more:
www.theopennotebook.com/2025/08/12/h...
Ageing accelerates around age 50 ― some organs faster than others, suggesting that ageing does not march to a steady beat @nature.com @heidiledford.bsky.social
www.nature.com/articles/d41...
Turbocharged ‘killer’ cells show promise for autoimmune disease @nature.com
@heidiledford.bsky.social
nature.com/articles/d41...
on
@cellcellpress.bsky.social
doi.org/10.1016/j.ce...
NIH director Jay Bhattacharya posted on X: "No clinical trial has been delayed, nor has any participant been dropped from clinical trial. These are the facts."
Malaria, tuberculosis, cancer trials abroad have all been on the chopping block, leaving participants stranded, I reported in this story.
After ruling the NIH grant cuts were illegal yesterday, Judge Young, a Reagan appointee on the bench since 1985, ended the hearing with a blistering 15-minute speech.
I've cleaned up my notes — here are his remarks in full. 🧵
An NIH staffer reacts to today's ruling:
"I'm looking forward to the day that we are so slammed with work trying to reinstate everything that we had to terminate illegally — I'll work 24/7 to make that happen if I can."
Caricature of McClintock by David Levine for The New York Review of Books.
Barbara McClintock was born OTD in 1902.
“I start with the seedling, and I don't want to leave it. I don't feel I really know the story if I don't watch the plant all the way along. So I know every plant in the field. I know them intimately, and I find it a real pleasure.”
🌱🐋🧪 #HistSTM #PhilSci
A lightning-fast, in-depth look into who RFK Jr selected for the vaccine advisory committee. One of whom was an expert witness against Merck's vaccine, despite RFK's stated reason of reducing conflicts of interest, per @reuters.com.
Well done @heidiledford.bsky.social and @rfieldmouse.bsky.social
"US scientists who find themselves abruptly unemployed are turning desperation and defiance into fresh coping strategies and advice. But one thing is clear: whether they move abroad, pivot to other research areas or leave science altogether, their deep expertise is likely to be lost." 🧪
Check out this news story that @nature.com wrote describing our recent preprint where we tested our H5 mRNA vaccine in calves.
The data look good and we are currently testing the vaccine in lactating cattle...more to come!
The CRISPR family’s most versatile member has made its medical debut: a cutting-edge gene-editing technique known as prime editing has been used to treat a person for the first time
https://go.nature.com/3YNta9V
Today the 1st case of CRISPR 3.0 (Prime genome editing) announced for a teenager with chronic granulomatous disease
www.nature.com/articles/d41...
So maybe the same will be true for these n=1 gene editing treatments. Or a new model for development/payment will emerge. Maybe this really will be the "future of medicine", a phrase that came up a lot in articles about KJ.
I have hope, I just don’t know how long it will take us to get there. 12/12
But…I remember back when cell therapies were deemed too complex and expensive to be commercially viable, and now look at all the CAR T cell therapies. (Those still need to be cheaper and less complex, too, but researchers are working on that. Step-by-step.) 11/12
Each therapy would have to be designed, tested, produced fresh for each recipient. Gene therapies and gene-editing therapies on the market now are already staggeringly expensive, and those companies can spread the cost of development over many recipients, not just one. 10/12
Lots of other parents of children with rare genetic disorders would like their kids to have more joy. For now, it’s hard to know how many of them will have an option like KJ. The usual biotech/commercial models won't work well for this. 9/12
Last year, I spoke to researchers who tried to develop a base-editing therapy for a young woman with a devastating genetic illness. www.nature.com/articles/d41...
They worked round the clock but didn't make it in time. Thankfully KJ’s case was different and, so far, he's doing well. 8/12
KJ’s parents decided to take a chance on CRISPR, and the clock started ticking. Gene editing therapies are complicated to design, test, produce. Each day brought added risk that KJ might die or become disabled. 7/12